In addition, aberrant splicing of genes involved in heme metabolism, such as TMEM14C, PPOX, and ABCB7, has been observed in MDS patients, particularly in those carrying SF3B1 mutations, suggesting that correction of splicing defects could potentially reverse defective erythropoiesis in these patients [32]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.